Summary of 18F-FDG PET Studies Conducted for Monitoring Responses to Cytostatic Therapies
| Agent | Author | Year | No. of patients | Phase of trials | Time after treatment when scanning was done | Change in SUVmax in partial responders* | Criteria for PET response | Outcome measure | Design | P |
|---|---|---|---|---|---|---|---|---|---|---|
| Imatinib | Banzo (33) | 2008 | 18 | NSp | Variable | NA | EORTC | Response | Prospective | NS |
| Holdsworth (34) | 2007 | 63 | NSp | 1 mo | 40% | NS | NS | |||
| Choi (35) | 2007 | 40 | NSp | 2 mo | 75% | >70% decrease | Response | Prospective | ||
| Simo Perdigo (36) | 2006 | 20 | NSp | 8–12 wk | 33%−67% | NS | Response | Prospective | ||
| Heinicke (37) | 2005 | 5 | NSp | 1 wk | 60% | NS | Response | NSp | NS | |
| Goerres (38) | 2005 | 34 | NSp | Variable | 55% | EORTC | 78% survival (95% CI = 63%−94%) | Prospective | NS | |
| Goldstein (39) | 2005 | 18 | NSp | NA | NA | EORTC | Prospective | NS | ||
| Jager (40) | 2004 | 16 | NSp | 1 wk | 65% | NS | Survival | 0.002 | ||
| Gayed (41) | 2004 | 49 | NSp | Variable | 51% | EORTC | Response | NSp | ||
| Choi (42) | 2004 | 36 | NSp | 2 mo | 64.9% | Modified EORTC | Response | Prospective | <0.0001 | |
| Antoch (43) | 2004 | 20 | NSp | 1, 3, and 6 mo | NA | EORTC | Response | Prospective | 0.04† | |
| Van Oosterom (7) | 2001 | 40 | I | 1 and 4 wk | NA | EORTC | Response | Prospective | ||
| Bevacizumab | Goshen (44) | 2006 | 7 | I | NA | NA | NS | Response and pathology | Retrospective | NS |
| Endostatin | Herbst (45) | 2002 | 25 | I | 28 and 56 d | 5%−69% | Variable | Response | Prospective | NS |
| Gefitinib | Sunaga (46) | 2008 | 5 | I | Day 2 and 4 wk | 61% on day 2 | NS | PFS of >12 mo | Prospective | NS |
| Lapatinib | Kawada (47) | 2007 | 8 | I | 1, 2, and 3 mo | 6%−42% | NS | Response | Prospective | NS |
| Cetuximab | De Fabio (48) | 2007 | 22 | II | At 6-wk intervals | >35% | <35% | Response | Prospective | NS |
| Tamoxifen or fulvestrant | Dehdashti (49) | 2008 | 51 | II | After 30 mg of estradiol | >12% increase, by ROC analysis | 20% | Response | Prospective | NS |
| Mortimer (50) | 2001 | 40 | II | 7–10 d | NA | 28.4% increase | Response | Prospective | NS | |
| Goserelin | Oyama (51) | 2001 | 10 | I | 1–5 mo | NA | 66.4% | Response | NSp | 0.04 |
↵* Decrease, unless otherwise indicated.
↵† Responses were correctly predicted in 85% of patients (3 mo) and 100% of patients (3 and 6 mo).
NSp = not specified; NS = not significant; NA = data not available; CI = confidence interval; PFS = progression-free survival; ROC = receiver operating characteristic.